CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%

CytoDyn Inc.

52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.
Each unit: one common share and one warrant (exercise $0.21, 5-year term).
Placement agent received 13% cash fee and warrants to purchase ~7.9M shares (10-year term).
Follow-on offering netted ~$0.2M in proceeds.
Aggregate unregistered sales exceeded 5% of shares outstanding as of March 28, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.